Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience
Authors:
Zdeněk Adam 1; Luděk Pour 1; Marta Krejčí 2; Sabina Ševčíková 2; Eva Pourová 3; Eva Ševčíková 1; Zdeněk Král 1; Jiří Mayer 1
Authors‘ workplace:
Interní hematologická a onkologická klinika LF MU a FN Brno, pracoviště Bohunice
1; Katedra patologické fyziologie LF MU Brno
2; Ordinace praktického lékaře pro dospělé, Pustiměř
3
Published in:
Vnitř Lék 2016; 62(1): 25-39
Category:
Reviews
Overview
Waldenström macroglobulinemia is defined by the presence of monoclonal immunoglobulin IgM type (M-IgM) and evidence of lymphoplasmacytic bone marrow infiltration. The disease has an indolent course, the treatment is only initiated when the disease has begun to damage its carrier. The following symptoms are regarded as proven indications for initiating therapy: B symptoms, symptomatic lymphadenopathy, splenomegaly, anemia with hemoglobin below 100 g / l or thrombocytopenia < 100 × 109/l, caused by lymphoplasmacytic bone marrow infiltration. Frequent indications for initiating treatment include clinical evidence of hyperviscosity or cryoglobulinemia. M-IgM tends to have a character of autoantibody reaching up to 50 %, which may harm the organism, and therefore any proven damage to the organism by an autoimmune activity of M-IgM is also an indication for treatment. The text includes an overview of rare and very rare types of damage to the organism by M-IgM autoimmune activity. A combination of rituximab, cyclophosphamide and dexamethasone (RCD) is recommended for the initial treatment, possibly extended to R-CHOP regimen (rituximab, cyclophosphamide, vincristine, doxorubicin and prednisone). In our cohort of 43 patients the therapy involving a combination of R-CHOP achieved 3 (8.1 %) complete remissions and 31 (83.8 %) partial remissions. The remission in 75 % of the patients lasted more than 3 years. In case of recurrence after > 2 years, the same therapy can be used, in case of a relapse within a shorter period of time different treatment schedules are recommended. High-dose chemotherapy with an autologous transplant of stem cells obtained from peripheral blood is only recommended after the first recurrence for people under 65 years of age without contraindications. The text analyses the benefits of the new drugs for the treatment of Waldenström macroglobulinemia (bendamustine, thalidomide, lenalidomide, ibrutinib and high-dose chemotherapy).
Key words:
autoimmunity – bendamustine – bortezomibe – hyperviscosity – ibrutinib – cryoglobulinemia – monoclonal immunoglobulin related disease – cold agglutinin disease – rituximab – Waldenström macroglobulinemia
Sources
1. Waldenström J. Incipient myelomatosis or essential hyperglobulinemia with fibrinogenopenia. A new syndrome? Acta Med Scand 1944; 117(3–4): 216–247. Dostupné z DOI: <http://dx.doi.org/10.1111/j.0954–6820.1944.tb03955.x>.
2. Owen RG, Treon SP, Al-Katib A et al. Clinicopathological definition of Waldneström macroglobulinaemia. Semin Oncol 2003; 30(2): 110–115.
3. Owen RG. Developing diagnostic criteria in Waldenstrom’s macroglobulinemia. Semin Oncol 2003; 30(2): 196–200.
4. Owen RG, Treon SP, Al-Katib A et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol 2003; 30(2): 110–115.
5. Rajkumar SV, Kyle R, Buadi F et al. Advances in the diagnosis classifications and management of monoclonal gammopathy of untertermined significance. Implication for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc 2010; 85(10): 945–948. Dostupné z DOI: <http://dx.doi.org/10.4065/mcp.2010.0520>.
6. Dimopoulos M, Kastritis E, Owen R et al. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood 2014; 124(9): 1404–1411.
7. Wang H, Chen Y, Li F et al. Temporal and geografic variations of Waldenström macroglobulinemia incidence. A large population based study. Cancer 2012; 118(15): 3793–3800. Dostupné z DOI: <http://dx.doi.org/10.1002/cncr.26627>.
8. Ailawadhi S, Kardosh A, Yang D et al. Outcome disparities among ethnic subgroups of Waldenström’s macroglobulinemia: a population-based study. Oncology 2014; 86(5–6): 253–262.
9. Castillo JJ, Olszewski AJ, Kanan S et al. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol 2015; 169(1): 81–89. Dostupné z DOI: <http://dx.doi.org/10.1111/bjh.13264>.
10. Kristinsson SY, Eloranta S, Dickman PW et al. Patterns of survival in lymphoplasmocytic lymphoma/Waldenström´s macroglobulinaemia: a population based study of 1555 patients diagnosed from 1980 to 2005. Amer J Hematol 2013; 88(1): 60–65.
11. Morel P, Duhamel A, Gobbi P et al. International prognostic scoring system for Waldenström macroglobulinemia. Blood 2009; 113(18): 4163–4170. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2008–08–174961>.
12. Kastritis E, Kyrtsonis MC, Hadjiharissi E et al. Greek Myeloma Study Group. Validation of the International Prognostic Scoring System (IPSS) for Waldenström’s macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). Leuk Res 2010; 34(10): 1340–1343.
13. Varettoni M, Tedeschi A, Arcaini L et al. Risk of second cancers in Waldenström macroglobulinemia. Ann Oncol 2012; 23(2): 411–415.
14. Morra E, Varettoni M, Tedeschi A et al. Associated cancers in Waldenström macroglobulinemia: clues for common genetic predisposition. Clin Lymphoma Myeloma Leuk 2013; 13(6): 700–703.
15. Castillo JJ, Olszewski AJ, Hunter ZR et al. Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database. Cancer 2015; 121(13): 2230–2236. Dostupné z DOI: <http://dx.doi.org/10.1002/cncr.29334>.
16. Adam Z, Šmardová J, Ščudla V. Waldenströmova makroglobulinemie – klinické projevy, diferenciální diagnostika a prognóza nemoci. Vnitř Lék 2007; 53(12): 1325–1337.
17. Malaviya AN, Kaushik P, Budhiraja S et al. Hypergammaglobulinemic purpura of Waldenström: report of 3 cases with a short review. Clin Exp Rheumatol 2000; 18(4): 518–522.
18. Michiels JJ, van Vliet HH. Acquired von Willebrand disease in monoclonalgammapathies: effectiveness of high-dose intravenous gamma globulin. Clin Appl Thromb Hemost 1999; 5(3): 152–157.
19. Zangari M, Elice F, Tricot G et al. Bleeding disorders associated with cancer dysproteinemias. Cancer Treat Res 2009; 148: 295–304.
20. Adam Z, Pour L, Krejčí M et al. Léčba Waldenströmovy makroglobulinemie. Zkušenosti jednoho pracoviště. Vnitř Lék 2009; 55(1): 9–17.
21. Ferri C, Sebastiani M, Giuggioli D et al. Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin’s lymphoma, and cancer. World J Hepatol 2015; 7(3): 327–343.
22. Stone MJ, McElroy A, Pestronk P et al. Human monoclonal macroglobulins with antibody activity. Semin Oncol 2003; 30(2): 318–324.
23. Stone MJ, Marlini V, Pascual F. Autoantibody activity in Waldenström´s macroglobulinaemia. Clin. Lymphoma 2005; 5(4): 225–229.
24. Antienza J, Bockorny B, Dadla A et al. Inflammatory and immune-releated condition associated with Waldenström´s macroglobulinemia. A single center experience. Leuk Lymphoma 2015; 56(4): 1179–1180.
25. Bockorny B, Antienza J, Dasanu CA. Autoimmune manifestation in Waldenström, macroglobulinemia. Clin Lymphoma Myeloma Leuk 2014; 14(6): 456–459.
26. Jonsson V, Kierkegaard A, Salling S et al. Autoimmunity in Waldenström´s macroglobulinemia. Leukemia Lymphoma 1999; 34(3–4): 373–379.
27. Urraro T, Gragnani L, Piluso A et al. Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy. Case Reports Immunol 2015; 2015: 816424. Dostupné z DOI: <http://dx.doi.org/10.1155/2015/816424>.
28. Cornella SL, Stine JG, Kelly et al. Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series. Postgrad Med 2015; 127(4): 413–417.
29. Ghetie D, Mehraban N, Sibley CH. Cold hard facts of cryoglobulinemia: updates on clinical features and treatment advances. Rheum Dis Clin North Am 2015; 41(1): 93–108.
30. Chang H, Qi C, Trieu Y et al. Prognostic relevance of 6q deletion in Waldenström’s macroglobulinemia: a multicenter study. Clin Lymphoma Myeloma 2009; 9(1): 36–38.
31. Nguyen-Khac F, Lambert J, Chapiro E et al. Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström’s macroglobulinemia. Haematologica 2013; 98(4): 649–654.
32. Sevčíková S, Novák L, Kubiczková L et al. Moleculární základy Waldenströmy makroglobulinemie. Klin Onkol 2012; 25(6): 413–420.
33. Treon SP, Xu L, Yang G et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med 2012; 367(9): 826–833.
34. Xu L, Hunter ZR, Yang G et al. Detection of MYD88 L265P in peripheral blood of patients with Waldenström’s macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Leukemia 2014; 28(8): 1698–1704.
35. Gachard N, Parrens M, Soubeyran I et al. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia 2013; 27: 183–189.
36. Landgren O, Staudt L. MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med 2012; 367(23): 2255–2256.
37. Treon SP, Cao Y, Xu L et al. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia. Blood 2014; 123(18): 2791–2796.
38. Ansell SM, Kyle RA, Reeder CB. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc 2010; 85(9): 824–833.
39. Buske C, Leblond V, Dimopoulos M et al. Waldenstrom’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(Suppl 6): S155-S159.
40. Vos JM, Minnema MC, Wijermans PW et al. Guideline for diagnosis and treatment of Waldenström’s macroglobulinaemia. Neth J Med 2013; 71(2): 54–62.
41. Kyle RA, Benson JT, Larson DR et al. Progression in smoldering Waldenström macroglobulinémie: long term results. Blood 2012; 119(19): 4462–4466.
42. Gertz MA. Waldestrom macroglobulinaemia: 2015 update on diagnosis, risk stratification and management. Amer J Hematol 2015; 90(4): 346–354.
43. Owen RG, Kyle RA, Stone MJ et al. Response assessment in Waldenström macroglobulinemia: update from the VIth international Worshop. Br J Haematol 2013; 160(2): 171–176.
44. Leblond V, Johnson S, Chevret S et al. Results of a randomised trial comparing chlorambucil versus fludarabine for patients with untreated Waldenström´s macroglobulinemia, marginal zone lymphoma or lymphoplasmocytic lymphoma. J Clin Oncol 2013; 31(3): 301–307.
45. Ramchandren S, Lewis RA. Monoclonal gammopathy and neuropathy. Curr Opin Neurol 2009; 22(5): 480–485.
46. Ghobrial IM, Fonseca R, Greipp PR et al. Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenström macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer 2004; 101(11): 2593–2598.
47. Treon SP, Hanzis C, Manning RJ. Maintenance rituximab is associated with improved clinical outcome in rituximab naive patients with Waldenström macroglobulinaemia who respond to a rituximab-containing regimen. Br J Haematol 2011; 154(3): 357–362.
48. Owen RG, Pratt G, Auer RL et al. British Committee for Standards in Haematology. Guidelines on the diagnosis and management of Waldenström macroglobulinaemia. Br J Haematol 2014; 165(3): 316–333.
49. Furman RR, Eradat H, DiRienzo CG et al. A phase II trial of ofatumumab in subjects with Waldenström’s macroglobulinemia. Blood (ASH Annual Meeting Abstracts) 2011; 118(21): Abstr 3701.
50. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007; 25(22): 3344–3349.
51. Dimopoulos MA, Roussou M, Kastritis E et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab and cyclophosphamide (DRC): Final analysis of phase II study. Blood (ASH Annual meeting abstracts) 2012; 120(21): Abstr 438.
52. Ioakimidis L, Patterson CJ, Hunter ZR et al. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma 2009; 9(1): 62–66.
53. Buske C, Hoster E, Dreyling M et al. German Low-Grade Lymphoma Study Group. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2009; 23(1): 153–161.
54. Treon SP, Hunter ZR, Barnagan AR. CHOP plus rituximab in Waldenström´s macroglobulinemia. Clin Lymphoma 2005; 5(4): 273–277.
55. Pour L, Horáková Z, Krejčí M et al. Výsledky léčby Waldenströmovy makroglobulinémie na IHOK FN Brno. XII. Pracovní konference na téma monoklonálních gamapatií. Hradec Králové 2013.
56. Dhodapkar MV, Jacobson JL, Gertz MA et al. Prognostic factors and response to fludarabine therapy in Waldenström’s macroglobulinemia: an update of a US intergroup trial (SW0G S9003). Semin Oncol 2003; 30(2): 220–225.
57. Tedeschi A, Benevolo G, Varettoni M et al. Fludarabine plus cyclophosphamide and rituximab in Waldenström macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer 2012; 118(2): 434–443.
58. Tedeschi A, Ricci F, Goldaniga MC et al. Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma Leuk 2013; 13(2): 231–234.
59. Leleu X, Soumerai J, Roccaro A et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009; 27(2): 250–255.
60. Peinert S, Tam CS, Prince HM et al. Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia. Leuk Lymphoma 2010; 51(12): 2188–2197.
61. Tedeschi A, Alamos SM, Ricci F et al. Fludarabine-based combination therapies for Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma 2009; 9(1): 67–70.
62. Treon SP, Branagan AR, Ioakimidis L et al. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood 2009; 113(16): 3673–3678.
63. Carney DA, Westerman DA, Tam CS et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia 2010; 24(12): 2056–2062.
64. Rummel MJ, Niederle N, Maschmeyer G et al. Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381(9873): 1203–1210.
65. Treon SP, Hanzis C, Tripsas C al. Bendamustine therapy in patients with relapsed or refractory Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011; 11(1): 133–135.
66. Tedeschi A, Picardi P, Ferrero S et al. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia. Leuk Lymphoma 2015; 56(9):2637–2642.
67. Vidal L, Gafter-Gvili A, Gurion R et al. Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia. Cochrane Database Syst Rev 2012; 9: CD009045. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD009045.pub2>.
68. Treon SP, Ioakimidis L, Soumerai JD et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05–180. J Clin Oncol 2009; 27(23): 3830–3835.
69. Chen C, Kouroukis CT, White D et al. Bortezomib in relapsed or refractory Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma 2009; 9(1): 74–76.
70. Ghobrial IM, Hong F, Padmanabhan S et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenström macroglobulinemia. J Clin Oncol 2010; 28(8):1422–1428.
71. Ghobrial IM, Xie W, Padmanabhan S et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström macroglobulinemia. Am J Hematol 2010; 85(9): 670–674.
72. Dimopoulos MA, Garcia-Sanz R, Gavriatopoulou M et al. Primary therapy of waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the european myeloma network (EMN). Blood 2013; 122(19): 3276–3282.
73. Treon SP, Tripsas CK, Meid K et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström’s macroglobulinemia. Blood 2014; 124(4): 503–510.
74. Dimopoulos MA, Terpos E, Kastritis E. Proteasome inhibitor therapy for Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma Leuk 2013; 13(2): 235–237.
75. Sacco A, Aujay M, Morgan B et al. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom’s Macroglobulinemia. Clin Cancer Res 2011; 17(7): 1753–1764.
76. Treon SP, Soumerai JD, Branagan AR et al. Thalidomide and rituximab in Waldenström macroglobulinemia. Blood 2008; 112(12): 4452–4457.
77. Treon SP, Soumerai JD, Branagan AR et al. Lenalidomide and rituximab in Waldenström’s macroglobulinemia. Clin Cancer Res 2009; 15(1): 355–360.
78. Nobile-Orazio E, Marmiroli P, Baldini L et al. Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins. Neurology 1987; 37(9): 1506–1514.
79. No autors listed. Ibrutinib Is Active in Refractory Waldenström Macroglobulinemia. Cancer Discov 2015; 5: OF 10. Dostupné z DOI: <http://dx.doi.org/10.1158/2159–8290.CD-RW2015–072>.
80. Treon SP, Tripsas CK, Meid K et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med 2015; 372(15): 1430–1440.
81. Cao Y, Hunter ZR, Liu X et al. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia. Leukemia 2015; 29(1): 169–176.
82. Ghobrial IM, Gertz M, Laplant B et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenström macroglobulinemia. J Clin Oncol 2010; 28(8): 1408–1414.
83. Treon SP, Tripsas CK, Ioakimidis L et al. Prospective, multicenter study of the mTOR inhibitor everolimus (RAD001) as primary therapy in Waldenström’s macroglobulinemia [abstract]. Blood 2011; 118(11): 2951.
84. Ghobrial IM, Witzig TE, Gertz M et al. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenström macroglobulinemia. Am J Hematol 2014; 89(3): 237–242.
85. Kyriakou C, Canals C, Sibon D et al. High-dose therapy and autologous stem-cell transplantation in Waldenström macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28(13): 2227–2232.
86. Chang H, Samiee S, Li D et al. Analysis of IgH translocations, chromosome 13q14 and 17p13.1(p53) deletions by fluorescence in situ hybridization in Waldenström’s macroglobulinemia: a single center study of 22 cases. Leukemia 2004; 18(6): 1160–1162.
87. Gertz MA, Reeder CB, Kyle RA et al. Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique. Bone Marrow Transplant 2012; 47(9): 1147–1153.
88. Usmani S, Sexton R, Crowley J et al. Autologous stem cell transplantation as a care option in Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011; 11(1): 139–142.
89. Bachanova V, Burns LJ. Hematopoietic cell transplantation for Waldenström macroglobulinemia. Bone Marrow Transplant 2012; 47(3): 330–336.
90. Adam Z, Hájek R, Krejčí M et al. Česká myelomová skupina. Doporučení pro diagnostiku a léčbu Waldenströmovy makroglobulinémie. Transfuze Hematologie Dnes 2014; 20(Suppl): S5-S22.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2016 Issue 1
Most read in this issue
- Toxic epidermal necrolysis
- Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience
- Significance of alanine aminotransferase screening in blood donors for risk reduction of hepatitis B and C transmission by haemotherapy
- Dangerous cucumbers – Leyll’s syndrome